Ustering of endemic Burkitt’s lymphoma in highrisk regions of Kenya. Int J Cancer. 2007; 120:12127. [PubMed: 17019706] 24. Hjalgrim H, Rostgaard K, Johnson Computer, Lake A, Shield L, Small AM, EkstromSmedby K, Adami HO, Glimelius B, HamiltonDutoit S, et al. HLAA alleles and infectious mononucleosis suggest a crucial function for cytotoxic Tcell response in EBVrelated Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2010; 107:6400405. [PubMed: 20308568] 25. Sumaya CV, Myers LW, Ellison GW. EpsteinBarr virus antibodies in several sclerosis. Arch Neurol. 1980; 37:946. [PubMed: 6243930] 26. Munger KL, Levin LI, O’Reilly EJ, Falk KI, Ascherio A. AntiEpsteinBarr virus antibodies as serological markers of many sclerosis: a prospective study amongst United states military personnel. Mult Scler. 2011; 17:1185193. [PubMed: 21685232] 27. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An updated metaanalysis of danger of several sclerosis following infectious mononucleosis. PLoS One. 2010:5. 28. Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, et al. Enhanced CD8 T cell response to EpsteinBarr virus lytic antigens inside the active phase of several sclerosis. PLoS Pathog. 2013; 9:e1003220. [PubMed: 23592979]NIHPA Author Manuscript NIHPA Author Manuscript NIHPA Author ManuscriptCurr Opin Virol. Author manuscript; out there in PMC 2015 June 01.BalfourPage29. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, BarOr A, Panzara M, Sarkar N, Agarwal S, et al. Bcell depletion with rituximab in relapsingremitting several sclerosis. N Engl J Med. 2008; 358:67688. [PubMed: 18272891] 30. Cohen JI, Mocarski ES, RaabTraub N, Corey L, Nabel GJ. The require and challenges for improvement of an EpsteinBarr virus vaccine. Vaccine. 2013; 31 (Suppl two):B19496. [PubMed: 23598481] 31. Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age certain prevalence of EpsteinBarr virus infection among men and women aged 69 years within the United states and components affecting its acquisition. J Infect Dis. 2013; 208:1286293. [PubMed: 23868878]NIHPA Author Manuscript NIHPA Author Manuscript NIHPA Author ManuscriptCurr Opin Virol. Author manuscript; accessible in PMC 2015 June 01.BalfourPageHighlights Prophylactic and therapeutic EBV vaccines happen to be tested but none is licensed. Finest progress to date: prevention of infectious mononucleosis by a gp350 vaccine. Troubles are lack of an animal model and finding the top immunogen and adjuvant. Prospects include prevention of mono, PTLD, MS, and treatment of EBVrelated cancer.1-(6-Bromonaphthalen-2-yl)ethanone site NIHPA Author Manuscript NIHPA Author Manuscript NIHPA Author ManuscriptCurr Opin Virol.5-Ethynyluridine uses Author manuscript; offered in PMC 2015 June 01.PMID:23255394 TableBalfourProspects, progress, and challenges in EBV vaccine developmentProgress Infectious mononucleosis was prevented inside a phase 2 study using a subunit gp350 vaccine [7]. A CD8 Tcell peptide vaccine was immunogenic with a hint of efficacy [11]. A vaccinia construct expressing EBV membrane glycoprotein was immunogenic and may well have reduced incidence of EBV infection in Chinese children [3]. A subunit gp350 vaccine was secure in pediatric renal transplant candidates [8]. A vaccinia recombinant vector expressing the tumorassociated viral antigens EBNA1 and LMP2 was secure and immunogenic [12]. Proof that a vaccine could perform: EBVspecific CD8 T cell responses are elevated in the course of active MS [28]; monoclonal antibodies t.
